Compare Stocks → The World's First '$20 Trillion Drug?' (From Behind the Markets) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:ADXSNASDAQ:ATOSNASDAQ:CLSNOTCMKTS:CPMDNASDAQ:JAGX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXSAyala Pharmaceuticals$0.55+1.9%$0.69$0.50▼$1.95$5.91M1.6220,557 shs426 shsATOSAtossa Therapeutics$1.52+1.3%$1.42$0.59▼$2.31$190.46M1.21.40 million shs854,366 shsCLSNImunon$2.22$1.80▼$15.75$13.91M2.27150,471 shs711 shsCPMDCannaPharmaRX$0.01$0.01$0.00▼$0.03$6.61M2.12684,304 shsN/AJAGXJaguar Health$0.17$0.09$0.05▼$1.22$46.96M1.3550.68 million shs19.25 million shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXSAyala Pharmaceuticals0.00%-16.34%-14.29%-10.00%-56.45%ATOSAtossa Therapeutics+0.67%+11.11%-20.63%+87.50%+136.26%CLSNImunon0.00%0.00%0.00%0.00%0.00%CPMDCannaPharmaRX0.00%0.00%-47.09%+733.33%+7.53%JAGXJaguar Health+1.13%+3.03%+135.32%+47.74%-64.38%Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (Ad)Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guideMarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/AATOSAtossa Therapeutics1.3893 of 5 stars3.51.00.00.02.81.70.0CLSNImunonN/AN/AN/AN/AN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXSAyala Pharmaceuticals2.00HoldN/AN/AATOSAtossa Therapeutics3.00Buy$4.50196.05% UpsideCLSNImunonN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/ACurrent Analyst RatingsLatest CLSN, JAGX, ATOS, CPMD, and ADXS Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/16/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.004/2/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$4.002/12/2024ATOSAtossa TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$4.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXSAyala Pharmaceuticals$10K591.25N/AN/A($2.27) per share-0.24ATOSAtossa TherapeuticsN/AN/AN/AN/A$0.73 per shareN/ACLSNImunon$500K0.00N/AN/A$9.66 per share0.00CPMDCannaPharmaRXN/AN/AN/AN/A($0.07) per shareN/AJAGXJaguar Health$9.76M4.81N/AN/A$0.07 per share2.43Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXSAyala Pharmaceuticals-$48.07M-$7.98N/A∞N/AN/A-3,967.23%-339.10%5/21/2024 (Estimated)ATOSAtossa Therapeutics-$30.09M-$0.24N/AN/AN/AN/A-31.01%-29.77%5/20/2024 (Estimated)CLSNImunon-$20.77MN/A0.00N/AN/A-5,229.80%-50.18%-36.94%N/ACPMDCannaPharmaRX-$8.53M-$0.03N/A∞N/AN/AN/A-141.66%N/AJAGXJaguar Health-$41.30MN/A0.00∞N/A-423.11%-837.11%-80.76%5/20/2024 (Estimated)Latest CLSN, JAGX, ATOS, CPMD, and ADXS EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails4/1/2024Q4 2023ATOSAtossa TherapeuticsN/A-$0.06-$0.06-$0.06N/AN/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthADXSAyala PharmaceuticalsN/AN/AN/AN/AN/AATOSAtossa TherapeuticsN/AN/AN/AN/AN/ACLSNImunonN/AN/AN/AN/AN/ACPMDCannaPharmaRXN/AN/AN/AN/AN/AJAGXJaguar HealthN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXSAyala PharmaceuticalsN/A0.300.30ATOSAtossa TherapeuticsN/A17.6117.61CLSNImunon0.136.526.52CPMDCannaPharmaRXN/AN/AN/AJAGXJaguar Health6.332.001.34OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXSAyala Pharmaceuticals7.18%ATOSAtossa Therapeutics12.74%CLSNImunon12.97%CPMDCannaPharmaRXN/AJAGXJaguar Health12.04%Insider OwnershipCompanyInsider OwnershipADXSAyala Pharmaceuticals0.63%ATOSAtossa Therapeutics7.80%CLSNImunon4.66%CPMDCannaPharmaRX1.27%JAGXJaguar Health0.16%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableADXSAyala PharmaceuticalsN/A10.75 million10.68 millionNot OptionableATOSAtossa Therapeutics12125.30 million115.53 millionOptionableCLSNImunon277.10 million6.77 millionOptionableCPMDCannaPharmaRX6660.63 million652.24 millionNot OptionableJAGXJaguar Health49276.22 million275.77 millionNo DataCLSN, JAGX, ATOS, CPMD, and ADXS HeadlinesSourceHeadline3 Obstacles Investors Face When Buying Penny Stockspennystocks.com - April 23 at 6:37 AMNapo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company's Expanding Focus on Cancer Supportive Careaccesswire.com - April 22 at 8:45 AMJaguar Health (NASDAQ:JAGX) Now Covered by StockNews.comamericanbankingnews.com - April 22 at 2:16 AMJaguar Health gets grant for treating secretory diarrhea associated with microvillous inclusion diseasepharmaceutical-technology.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry…pharmiweb.com - April 18 at 11:23 AMJaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Careaccesswire.com - April 18 at 8:30 AMJaguar Health licenses Venture Life's US FDA-approved oral mucositis product, Gelclair for US marketpharmabiz.com - April 18 at 6:22 AMWhy Jaguar Health Stock Is Up Todaymsn.com - April 17 at 2:20 AMGold Moves Higher; Morgan Stanley Earnings Top Viewsmarkets.businessinsider.com - April 17 at 2:20 AMWhy Is Jaguar Health (JAGX) Stock Up 44% Today?investorplace.com - April 16 at 11:34 AMJaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Careaccesswire.com - April 16 at 8:30 AMS&P 500 Down 1%; Delta Air Lines Posts Upbeat Earningsbenzinga.com - April 10 at 3:37 PMJaguar Health shareholders approve reverse stock splitmsn.com - April 10 at 3:37 PMWhat Is Going on With Jaguar Health (JAGX) Stock Today?investorplace.com - April 10 at 10:40 AMJaguar Health, Inc.: Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersfinanznachrichten.de - April 10 at 1:23 AMWhy Jaguar Health Stock Is Soaring After-Hoursmsn.com - April 9 at 8:04 PMJaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholdersaccesswire.com - April 9 at 4:15 PMJaguar Health Granted Extension Until August 13, 2…pharmiweb.com - April 8 at 9:51 AMJaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirementaccesswire.com - April 8 at 8:30 AMJaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)finance.yahoo.com - April 3 at 9:48 AMJaguar Health, Inc. (NASDAQ:JAGX) Q4 2023 Earnings Call Transcriptfinance.yahoo.com - April 2 at 1:47 PMJaguar Health Appoints European Pharmaceutical Industry Leader as President of Jaguar Internationalaccesswire.com - April 2 at 8:50 AMJAGX Stock Earnings: Jaguar Health Misses Revenue for Q4 2023investorplace.com - April 1 at 2:08 PMJaguar Health, Inc.: Jaguar Health Reports 2023 Financial Resultsfinanznachrichten.de - April 1 at 10:51 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsAyala PharmaceuticalsNASDAQ:ADXSAyala Pharmaceuticals, Inc., a clinical-stage oncology company, primarily focuses on developing and commercializing small molecule therapeutics for people living with rare tumors and aggressive cancers. The company's lead candidates under development include AL102, an oral gamma secretase inhibitor for desmoid tumors; and aspacytarabine (BST-236), a novel proprietary anti-metabolite for first line treatment in unfit acute myeloid leukemia. Ayala Pharmaceuticals, Inc. is based in Wilmington, Delaware.Atossa TherapeuticsNASDAQ:ATOSAtossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing medicines in the areas of unmet medical need in oncology. The company's lead program is Endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It is also developing AT-H201 for lung injury caused by cancer treatment. In addition, the company develops immunotherapy/chimeric antigen receptor therapy programs. It has a research agreement with Dana-Farber Cancer Institute, Inc. to support research of cytokine-coated nanoparticles for the treatment of breast cancer. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.ImunonNASDAQ:CLSNCelsion Corporation, a clinical stage biotechnology company, focuses on the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. Its product pipeline includes GEN-1, a DNA-based immunotherapy for the localized treatment of ovarian cancer; and ThermoDox, a proprietary heat-activated liposomal encapsulation of doxorubicin, which is in development stage for various cancer indications. The company also has two feasibility stage platform technologies for the development of nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Celsion Corporation was founded in 1982 and is based in Lawrenceville, New Jersey.CannaPharmaRXOTCMKTS:CPMDCannaPharmaRX, Inc. operates in the cannabis industry in Canada. It evaluates, negotiates, acquires, and develops various cannabis cultivation projects. The company was incorporated in 1998 and is based in Calgary, Canada.Jaguar HealthNASDAQ:JAGXJaguar Health, Inc., a commercial stage pharmaceuticals company, focuses on developing prescription medicines for people and animals with gastrointestinal distress, specifically chronic and debilitating diarrhea. The company operates through two segments, Human Health and Animal Health. It markets Mytesi for the symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company also develops Crofelemer, which is in Phase 3 clinical trial for or prophylaxis of diarrhea in adult cancer patients, and to address rare/orphan disease indications, including Short bowel syndrome with intestinal failure and/or congenital diarrheal disorders; supportive care for diarrhea relief in inflammatory bowel diseases; diarrhea-predominant irritable bowel syndrome; and for idiopathic/functional diarrhea. In addition, it develops NP-300, a second-generation proprietary anti-secretory antidiarrheal drug for symptomatic relief and treatment of moderate-to-severe diarrhea; and Canalevia, an oral plant-based drug candidate to treat chemotherapy-induced diarrhea in dogs and exercise-induced diarrhea in dogs. The company was founded in 2013 and is headquartered in San Francisco, California. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.